Conference Proceedings

Pre-specified interim analysis of GALAHAD: A phase II study of niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD)

MR Smith, SK Sandhu, WK Kelly, HI Scher, E Efstathiou, N Lara, EY Yu, DJ George, KN Chi, F Saad, J Summa, JM Freedman, GE Mason, E Zhu, D Ricci, JS Simon, S Cheng, K Fizazi

ANNALS OF ONCOLOGY | OXFORD UNIV PRESS | Published : 2019

Grants

Funding Acknowledgements

Janssen Research & Development, LLC.